pPACK-SPIKE SARS-CoV-2 S Pseudotype Lentivector Packaging Mix
Product Description
- Based on SBI’s popular and highly cited pPACKH1 Packaging System
- Uses codon-optimized SARS-CoV-2 “S" protein in place of VSV-G envelope protein
- Ideal for COVID-19 research, such as neutralization assays, under BSL2 conditions
- Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
- Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control
Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE SARS-CoV-2 “S" Pseudotype Lentivector Packaging Mix speeds and simplifies the preparation of lentiviral particles pseudotyped with the SARS-CoV-2 Spike glycoprotein. Based on SBI’s highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 Spike protein1 replacing the standard VSV-G envelope protein, the pPACK-SPIKE Packaging Mix consists of three plasmids that produce all of the structural and replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, “Spike" pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.
For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for pPACK-SPIKE studies, or for creating lentivirus particles pseudotyped with the envelope protein of your choice.
pPACK-SPIKE SARS-CoV-2 "S" Pseudotype Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient Combo Kit that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution.
How It Works
pPACK-SPIKE is easy to use - simply co-transfect the pPACK-SPIKE Plasmids and your lentivector construct into 293TN producer cells or other lentiviral production cells, isolate pseudoviral particles with an optional concentration step, and conduct your studies.
Available pPACK-SPIKE S protein variants
Catalog Number | Spike Variant | WHO label | Spike Protein Mutation |
CVD19-500A-1-SBI | SARS-CoV-2 “S” Pseudotype | Original Wuhan-Hu-1 strain | |
CVD19-530A-1-SBI | D614G Mutant | D614G | |
CVD19-560A-1-SBI | N501Y Mutant | N501Y | |
CVD19-590A-1-SBI | B.1.1.7 (UK) Variant | Alpha | ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H |
CVD19-580A-1-SBI | B.1.351 (S.A.) RBD Mutations | Beta | K417N, E484K, & N501Y |
CVD19-600A-1-SBI | B.1.351 (S.A.) S1 Mutations (RBD+D614G) | Beta | K417N, E484K, N501Y, & D614G |
CVD19-640A-1-SBI | B.1.351 (S.A.) complete spike mutations | Beta | ΔH69/V70, Q52R, E484K, D614G, Q677H, F888L |
CVD19-610A-1-SBI | B.1.429 (CAL.20C) Variant | Epsilon | S13I, W152C, L452R, & D614G |
CVD19-620A-1-SBI | B.1.525 Variant | Eta | ΔH69/V70, Q52R, E484K, D614G, Q677H, & F888L |
CVD19-630A-1-SBI | P1 Variant | Gamma | L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F |
CVD19-650A-1-SBI | B.1.617.2 Variant | Delta | T19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N |
CVD19-660A-1-SBI | B.1.1.529 Variant | Omicron | A67V, Δ69-70, T95I, Δ142-144, Y145D, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S,Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F |
References
- Ou X, et al. (2020) Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun.
- Catalog Number
CVD19-500A-1-SBI - Supplier
SBI System Biosciences - Size
- Shipping
Blue Ice